Stephen L. Bandak

Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds.

Hapten Sciences, Inc. is a biopharmaceutical company. It identifies and develops novel, early-stage products that contribute to the health and well being of people around the world. Its product include PDC-APB, a small molecule that acts like a vaccine to prevent the extremely painful itching and rash. The company was founded by Raymond Joseph Hage Jr. and is headquartered in Memphis, TN.

Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland.

Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA.